JP2022505257A - α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン - Google Patents
α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン Download PDFInfo
- Publication number
- JP2022505257A JP2022505257A JP2021521219A JP2021521219A JP2022505257A JP 2022505257 A JP2022505257 A JP 2022505257A JP 2021521219 A JP2021521219 A JP 2021521219A JP 2021521219 A JP2021521219 A JP 2021521219A JP 2022505257 A JP2022505257 A JP 2022505257A
- Authority
- JP
- Japan
- Prior art keywords
- polymorph
- composition
- diene
- ipa
- trimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 49
- 208000034799 Tauopathies Diseases 0.000 title claims abstract description 14
- IJWAQTHZBDBIID-UHFFFAOYSA-N 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione Chemical compound CCCCCCCCCC1=C(C)C(=O)C(C)=C(C)C1=O IJWAQTHZBDBIID-UHFFFAOYSA-N 0.000 title claims description 44
- 229940125334 utreloxastat Drugs 0.000 title claims description 39
- 208000032859 Synucleinopathies Diseases 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 163
- 150000001875 compounds Chemical class 0.000 claims abstract description 115
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 21
- 230000006378 damage Effects 0.000 claims abstract description 21
- 208000014674 injury Diseases 0.000 claims abstract description 21
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 claims abstract description 19
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 18
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 16
- 230000009529 traumatic brain injury Effects 0.000 claims abstract description 16
- 125000004151 quinonyl group Chemical group 0.000 claims abstract description 12
- 239000012453 solvate Substances 0.000 claims abstract description 12
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 137
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 130
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 87
- 229910001868 water Inorganic materials 0.000 claims description 85
- 239000002245 particle Substances 0.000 claims description 84
- 239000002904 solvent Substances 0.000 claims description 49
- 208000018737 Parkinson disease Diseases 0.000 claims description 44
- 208000035475 disorder Diseases 0.000 claims description 41
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 28
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 28
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 27
- -1 carrier Substances 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims description 21
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 20
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000008018 melting Effects 0.000 claims description 15
- 238000002844 melting Methods 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 13
- 208000028867 ischemia Diseases 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 9
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 8
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 8
- 229910052709 silver Inorganic materials 0.000 claims description 8
- 239000004332 silver Substances 0.000 claims description 8
- 238000002411 thermogravimetry Methods 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 238000001757 thermogravimetry curve Methods 0.000 claims description 6
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 206010034010 Parkinsonism Diseases 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 3
- 229940102223 injectable solution Drugs 0.000 claims description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 102100037991 85/88 kDa calcium-independent phospholipase A2 Human genes 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 101710125553 PLA2G6 Proteins 0.000 claims description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
- 208000005400 Synovial Cyst Diseases 0.000 claims description 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000001054 cortical effect Effects 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 208000017004 dementia pugilistica Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- RUTPPUIUWZKKCU-UHFFFAOYSA-N CC=1CC(=C(CC=1C)C)CCCCCCCCC Chemical compound CC=1CC(=C(CC=1C)C)CCCCCCCCC RUTPPUIUWZKKCU-UHFFFAOYSA-N 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 239000007787 solid Substances 0.000 description 49
- 239000000463 material Substances 0.000 description 47
- 239000000243 solution Substances 0.000 description 46
- 239000000523 sample Substances 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000003981 vehicle Substances 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 238000001953 recrystallisation Methods 0.000 description 30
- 238000009826 distribution Methods 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 230000037396 body weight Effects 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- 239000013078 crystal Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 230000002776 aggregation Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 102000013498 tau Proteins Human genes 0.000 description 14
- 108010026424 tau Proteins Proteins 0.000 description 14
- 238000004220 aggregation Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000002002 slurry Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000012535 impurity Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 208000006011 Stroke Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 238000000386 microscopy Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 238000003801 milling Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000004547 Glucosylceramidase Human genes 0.000 description 6
- 108010017544 Glucosylceramidase Proteins 0.000 description 6
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 6
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 6
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 6
- 102000007659 Protein Deglycase DJ-1 Human genes 0.000 description 6
- 229940045835 RSL3 Drugs 0.000 description 6
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000003137 locomotive effect Effects 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- 102000045222 parkin Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 5
- BLCDNZKKQMHFLJ-UHFFFAOYSA-N 2-heptyl-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CCCCCCCC1=C(C(=O)C(=C(C1=O)C)C)C BLCDNZKKQMHFLJ-UHFFFAOYSA-N 0.000 description 5
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- TXJZRSRTYPUYRW-NQIIRXRSSA-N methyl (1s,3r)-2-(2-chloroacetyl)-1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate Chemical compound C1([C@H]2C3=C(C4=CC=CC=C4N3)C[C@@H](N2C(=O)CCl)C(=O)OC)=CC=C(C(=O)OC)C=C1 TXJZRSRTYPUYRW-NQIIRXRSSA-N 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 4
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 102100027831 14-3-3 protein theta Human genes 0.000 description 3
- QHXAJKMPZGFJRM-UHFFFAOYSA-N 2,3,5-trimethyl-6-octylcyclohexa-2,5-diene-1,4-dione Chemical compound CCCCCCCCC1=C(C)C(=O)C(C)=C(C)C1=O QHXAJKMPZGFJRM-UHFFFAOYSA-N 0.000 description 3
- QIXDHVDGPXBRRD-UHFFFAOYSA-N 2,3,5-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C(C)=C(C)C1=O QIXDHVDGPXBRRD-UHFFFAOYSA-N 0.000 description 3
- 102100026882 Alpha-synuclein Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010057430 Retinal injury Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 210000004002 dopaminergic cell Anatomy 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
- AUFZRCJENRSRLY-UHFFFAOYSA-N 2,3,5-trimethylhydroquinone Chemical compound CC1=CC(O)=C(C)C(C)=C1O AUFZRCJENRSRLY-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000010249 dopaminergic function Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical compound OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 229910016860 FaSSIF Inorganic materials 0.000 description 1
- 229910005429 FeSSIF Inorganic materials 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
- 239000005293 duran Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000001682 neurofibril Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000010815 organic waste Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
- C07C50/04—Benzoquinones, i.e. C6H4O2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C07C46/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
特許請求される結晶形態に関し、残留溶媒は許容限度内にあり、医薬組成物への製剤化に十分適したものにする。固体状態の形態は、結晶化技法を介した精製を容易にすることも可能である。特許請求される結晶形態は、吸湿性でも水和物/溶媒和物でもなく、これは湿度曝露に関して特殊な取扱いを必要としないことを意味する。さらに、再結晶化プロセスから得られる改善されたモルホロジーは、製造中のより容易な取扱いを可能にする(本明細書で、より詳細に記載されるように)。本明細書に記載される化合物は、薬学的に許容される賦形剤、薬学的に許容される担体、および薬学的に許容されるビヒクルなどの添加剤との製剤化によって、医薬組成物として製剤化することができる。適切な薬学的に許容される賦形剤、担体、およびビヒクルには、加工剤(processing agent)および薬物送達改質剤および増強剤、例えば、一部の実施形態では、リン酸カルシウム、ステアリン酸マグネシウム、タルク、単糖、二糖、デンプン、ゼラチン、セルロース、メチルセルロース、ナトリウムカルボキシメチルセルロース、デキストロース、ヒドロキシプロピル-β-シクロデキストリン、ポリビニルピロリドン、低融点ワックス、およびイオン交換樹脂など、ならびにこれらの2種またはそれよりも多くの組合せが含まれる。他の適切な薬学的に許容される賦形剤は、参照により本明細書に組み込まれる"Remington's Pharmaceutical Sciences," Mack Pub. Co., New Jersey (1991)、および"Remington: The Science and Practice of Pharmacy," Lippincott Williams & Wilkins, Philadelphia, 20th edition (2003) and 21st edition (2005)に記載される。
本発明の化合物は、本明細書に提供される開示に鑑み当業者に明らかになる一般的な方法および手順を使用して、容易に入手可能な出発材料から調製することができる。典型的なまたは好ましいプロセス条件(即ち、反応温度、時間、反応物のモル比、溶媒、圧力など)が与えられる場合、他に記述しない限り、他のプロセス条件も使用することができることが理解されよう。最適な反応条件は、使用される特定の反応物または溶媒と共に変動し得るが、そのような条件は、通常の最適化手順によって当業者が決定することができる。C9の溶液は光感受性であり;室内照明は、理想的には波長<450nmを除去するようにフィルタリングされるべきである(暗室灯フィルター)。暗室照明が利用できない場合には、適切な制御、例えばアルミ箔のラッピング、琥珀色のガラス製品を使用して、溶液の光曝露を最小限に抑えるべきである。
概要。生成物を、NaCl前処理後、2-プロパノール(IPA)/水(H2O)から再結晶化した後、消化、収集、ならびに空気および真空を介して乾燥することによって調製した。出発材料(実施例1Aで調製されたC9、99.9g)は高いAg含量(45ppm)を有しており、したがってブライン洗浄および2回の水洗浄を、C9化合物のメチルtert-ブチルエーテル(MTBE)溶液に行った後、乾燥し再結晶化した。C9のMTBE溶液を、2.7μmのフィルターに通して濾過して、塩化ナトリウム(NaCl)洗浄後に存在するいかなる微粒子も除去した。MTBEから再結晶化溶媒IPAへの溶媒交換中、褐色の固体が溶液中に形成され、高温濾過して除去する必要があった。黄褐色の固体は、キノン溶液の光曝露から生じた可能性が高く、さらに分析しなかった。次いで濾過した鮮黄色の溶液を光から保護し、濃縮し、85%のIPA/H2O(486g/98g)に40℃で溶解した。熱を除去し、結晶が35℃で形成した。スラリーを48時間、16℃で撹拌し、0℃に冷却し、固体を収集し、洗浄し、乾燥して、空気および真空下(約125mmHg)で一定の重量にして、82.1gの微細な黄色の針を得た(82.1%)。材料を、NMR、UPLC、LCMS、IR、およびMPによって分析した。
実施例1Aおよび3Aに示されるように、C9を作製するための合成方法は、高い銀含量、生成物の粘着性、ならびに望ましくない粒径および分布など、1つまたは複数の望ましくない特徴を有する生成物をもたらした。上で論じたように、再結晶化は、生成物の特性を改善し得る。したがって、様々な溶媒を、C9の再結晶化における適切さに関してスクリーニングした。
概要。この実施例は、10gのエンジニアリングバッチ上でのC9の再結晶化、およびその後に続く2.4kgのC9の再結晶化についてまとめる(両方の試料は実施例3Aから提供された通りである)。材料を2-プロパノールに40℃で溶解した後、水を添加して曇った溶液を達成し、これをジャケット付きフィルターに40℃で通してポリッシュフィルタリングした。得られた透明溶液をゆっくりと32℃に冷却し、それによって生成物は、微細な黄色の針として自発的に結晶化した。さらに段階的に16℃に、次いで0℃に冷却することによりスラリーを得、これを濾過により収集し、水中85%の2-プロパノールですすいだ。得られた固体を25℃で真空乾燥して、一定の重量にして、82%の回収で生成物(1.975kg)を得た。単離された固体を、DSC、IR、および1H NMRで試験し、合格であった。
概要
概要。
概要。実施例3A(粗製)および3B(再結晶化)からのC9に関する粒径分布を、Malvern 3000 Mastersizerを使用して決定した。
初期スクリーニングを行って、PDおよびADの改善のための化合物の有効性を同定した。試験試料および溶媒対照を、Jauslin et al., Hum. Mol. Genet. 11(24):3055 (2002)、Jauslin et al., FASEB J. 17:1972-4 (2003)、および国際特許出願WO 2004/003565に記載されるものに類似の手法でL-ブチオニン-(S,R)-スルホキシミン(BSO、GSHシンセターゼの特異的阻害剤)および鉄(例えば、クエン酸鉄)の添加によってストレスがかかったPDおよびAD線維芽細胞をレスキューする能力に関して試験した。この特異的BSO媒介細胞死は、本明細書に記載される化合物の投与によって予防または改善された。
概要:化合物2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン(「C9」)およびそのC8(2,3,5-トリメチル-6-オクチルシクロヘキサ-2,5-ジエン-1,4-ジオン)およびC7(2,3,5-トリメチル-6-ヘプチルシクロヘキサ-2,5-ジエン-1,4-ジオン)類似体を、タンパク質凝集の動態における誘導期の存在および程度によって測定される、αシヌクレイン凝集の阻害剤としてのそれらの機能に関して試験した。凝集体結合フルオロフォア、チオフラビンTによる蛍光強度の変化を追跡して、時間の関数としてのタンパク質凝集に関して報告した。
概要:化合物2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン(C9)、2,3,5-トリメチル-6-オクチルシクロヘキサ-2,5-ジエン-1,4-ジオン(C8)、および2,3,5-トリメチル-6-ヘプチルシクロヘキサ-2,5-ジエン-1,4-ジオン(C7)を、経時的な凝集体結合フルオロフォア、チオフラビンTの蛍光強度の減少によって測定される、ヒト野生型タウK18断片の予備形成フィブリル(PFF)を脱凝集するそれらの能力に関して試験した。
N27ラットドーパミン作動性細胞(EMD Milliporeから購入、SCC048)を形質転換して、Origeneから得たプラスミド構築物(RG221446)で緑色の蛍光タンパク質(GFP)と融合した切断型α-シヌクレインを安定的に過剰発現させた。細胞を、10%(v/v)ウシ胎仔血清(Millipore、ES-009-B)、1%(v/v)ペニシリン-ストレプトマイシン(Gibco、15140-122)、1%(v/v)L-グルタミン(Gibco、25030-081)、および500μg/mLのG418(Gibco、10131-027)を補充したRPMI 1640培地からなる選択培地中で維持した。
概要
300mg/kg用量のC9を、4匹のC57BL/6マウスに、経口強制給餌を介してゴマ油溶液として投与した。化合物投与の8時間後、血漿および脳の曝露を測定した(表10)。
Claims (62)
- 前記化合物が、溶媒和物でも水和物でもない、請求項1に記載の方法。
- 前記化合物が、キノン形態にある、請求項1または2に記載の方法。
- 前記化合物が、ヒドロキノン形態にある、請求項1または2に記載の方法。
- α-シヌクレインパチーを処置または抑制するためのものである、請求項1に記載の方法。
- 前記α-シヌクレインパチーが:パーキンソン病、認知症を伴うパーキンソン病(PDD)、多系統萎縮症(MSA)、前頭側頭型認知症、レビー小体型認知症(DLB)、ゴーシェ病(GD)、脳の鉄蓄積を伴う神経変性(NBIA)、および神経軸索ジストロフィー(PLA2G6関連神経変性)からなる群より選択される、請求項5に記載の方法。
- 前記パーキンソン病が、遺伝的である、請求項6に記載の方法。
- 前記パーキンソン病が、特発性である、請求項6に記載の方法。
- タウオパチーを処置または抑制するためのものである、請求項1に記載の方法。
- 前記タウオパチーが:アルツハイマー病、ボクサー認知症、グアムの筋萎縮性側索硬化症-パーキンソニズム-認知症(Guam ALS/PD)、ピック病、嗜銀顆粒性認知症、ニーマン-ピック病C型、亜急性硬化性全脳炎(SSPE)、進行性核上麻痺(PSP)、多系統萎縮症(MSA)、大脳皮質基底核神経節変性、パーキンソニズム-17を伴う前頭側頭型認知症(FTDP-17)、脳炎後パーキンソニズム(PEP)、および常染色体劣性パーキンソニズムからなる群より選択される、請求項9に記載の方法。
- アルツハイマー病を処置または抑制するためのものである、請求項1から4のいずれか一項に記載の方法。
- パーキンソン病を処置または抑制するためのものである、請求項1から4のいずれか一項に記載の方法。
- 外傷性脳損傷を処置または抑制するためのものである、請求項1から4のいずれか一項に記載の方法。
- 虚血-再潅流関連損傷を処置または抑制するためのものである、請求項1から4のいずれか一項に記載の方法。
- 卒中を処置または抑制するためのものである、請求項1から4のいずれか一項に記載の方法。
- 筋萎縮性側索硬化症(ALS)を処置または抑制するためのものである、請求項1から4のいずれか一項に記載の方法。
- 障害を処置するためのものである、請求項1から16のいずれか一項に記載の方法。
- 障害を抑制するためのものである、請求項1から16のいずれか一項に記載の方法。
- 前記化合物が、経口投与される、請求項1から18のいずれか一項に記載の方法。
- 前記化合物が、静脈内投与される、請求項1から18のいずれか一項に記載の方法。
- 2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンの無水物の多形であって、前記多形に関する粉末X線回折パターンが少なくとも次の角度位置:4.10、12.12、および16.14で特徴的ピークを含み、前記角度位置が±0.2変動し得る、多形。
- 少なくとも次の角度位置:4.10、11.77、12.12、および16.14で特徴的ピークを含み、前記角度位置が、±0.2変動し得る、請求項21に記載の多形。
- 少なくとも次の角度位置:4.10、11.77、12.12、16.14、および22.41で特徴的ピークを含み、前記角度位置が、±0.2変動し得る、請求項21に記載の多形。
- 前記角度位置が、±0.1変動し得る、請求項21から23のいずれか一項に記載の多形。
- 前記角度位置が、±0.05変動し得る、請求項21から23のいずれか一項に記載の多形。
- 図5、11、14、および16のいずれか1つで実質的に示されるような粉末x線回折パターンを有する、請求項21から25のいずれか一項に記載の多形。
- 図7に実質的に示されるような示差走査熱量測定(DSC)サーモグラムを有する、請求項21から26のいずれか一項に記載の多形。
- DSCサーモグラムが、約47から約53℃で単一の吸熱ピークを有する、請求項21から27のいずれか一項に記載の多形。
- 図8に実質的に示されるような熱重量分析(TGA)サーモグラムを有する、請求項21から28のいずれか一項に記載の多形。
- 図6に実質的に示されるような1H NMRスペクトルを有する、請求項21から29のいずれか一項に記載の多形。
- 請求項21から30のいずれか一項に記載の多形を含む組成物であって、あらゆる溶媒、担体、または賦形剤を除き、前記2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンの少なくとも約95モル%が、前記多形である、組成物。
- 請求項21から30のいずれか一項に記載の多形を含む組成物であって、あらゆる溶媒、担体、または賦形剤を除き、前記2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンの少なくとも約99モル%が、前記多形である、組成物。
- あらゆる溶媒、担体、または賦形剤を除き、前記組成物のHPLCにより測定された少なくとも約95%a/aが、前記2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンである、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31もしくは32に記載の組成物。
- あらゆる溶媒、担体、または賦形剤を除き、前記組成物のHPLCにより測定された少なくとも約99%a/aが、前記2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンである、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31もしくは32に記載の組成物。
- 前記2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンの効力が、少なくとも約95%である、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31から34のいずれか一項に記載の組成物。
- 前記2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンの効力が、少なくとも約99%である、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31から34のいずれか一項に記載の組成物。
- 前記多形が、複数の粒子として存在し、前記粒子が、約11:1未満のD90:D10の比を有する、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31から36のいずれか一項に記載の組成物。
- 前記多形が、複数の粒子として存在し、前記粒子が、約7:1未満のD90:D10の比を有する、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31から36のいずれか一項に記載の組成物。
- 前記多形が、約75~85%のIPA/水を含む溶媒によって再結晶化された、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31から38のいずれか一項に記載の組成物。
- 前記多形が、約80~85%のIPA/水を含む溶媒によって再結晶化された、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31から39のいずれか一項に記載の組成物。
- 前記多形が、約85%のIPA/水を含む溶媒によって再結晶化された、請求項21から30のいずれか一項に記載の多形を含む組成物または請求項31から39のいずれか一項に記載の組成物。
- 請求項21から30のいずれか一項に記載の多形、または請求項31から41のいずれか一項に記載の組成物、および薬学的に許容される溶媒、担体、もしくは賦形剤を含む医薬組成物、あるいは請求項21から30のいずれか一項に記載の多形、または請求項31から41のいずれか一項に記載の組成物、および薬学的に許容される溶媒、担体、もしくは賦形剤で調製される医薬組成物。
- α-シヌクレインパチー、タウオパチー、筋萎縮性側索硬化症(ALS)、外傷性脳損傷、または虚血-再潅流関連損傷を処置または抑制する方法であって、治療有効量の請求項21から30のいずれか一項に記載の多形または請求項31から42のいずれか一項に記載の組成物を、それを必要とする個体に投与することを含む、方法。
- 組成物から2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンを再結晶化させる方法であって、
a)約40~45℃の温度で、前記組成物をIPAおよび水と接触させて、得られるIPAの水に対する比が、約75~87%のイソプロパノール(IPA)/25~13%の水(v:v)になるようにすること、
b)混合物を約32℃に冷却すること、および
c)前記2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンを前記混合物から濾過すること
を含む、方法。 - ステップ(a)が、
a1)前記組成物をIPAと接触させること、
a2)前記混合物を約40~45℃に温めること、および
a3)水を前記混合物に添加して、前記IPAの水に対する比が約75~85%のIPA:25~15%の水(v:v)になるようにすること
を含む、請求項54に記載の方法。 - ステップ(a)が、前記組成物が溶解するように撹拌することを含む、請求項54に記載の方法。
- 前記IPA:水の比が、約80~85%のIPA:20~15%の水(v:v)である、請求項54から56のいずれか一項に記載の方法。
- 前記IPA:水の比が、約85%のIPA:15%の水(v:v)である、請求項54から56のいずれか一項に記載の方法。
- ステップ(a3)が、前記混合物の温度を約40~45℃に戻すことを含む、請求項54から58のいずれか一項に記載の方法。
- ステップ(a)後に前記混合物をポリッシュフィルタリングすることを含む、請求項54から58のいずれか一項に記載の方法。
- ステップ(b)が、約2~10時間にわたって約32℃に冷却することを含む、請求項54から59のいずれか一項に記載の方法。
- ステップ(b)が、約6時間にわたって約32℃に冷却することを含む、請求項54から59のいずれか一項に記載の方法。
- ステップ(b)の後に、前記混合物を約2~24時間、約32℃で保持することを含むステップ(b1)を含む、請求項54から61のいずれか一項に記載の方法。
- ステップ(b)の後に、前記混合物を約6時間、約32℃で保持することを含むステップ(b1)を含む、請求項54から61のいずれか一項に記載の方法。
- 存在する場合にはステップ(b)または(b1)の後に、前記混合物を約0℃に冷却することを含むステップ(b2)を含む、請求項54から63のいずれか一項に記載の方法。
- ステップ(b2)が、前記混合物を約3~24時間にわたって約0℃に冷却することを含む、請求項54から63のいずれか一項に記載の方法。
- ステップ(b2)が、前記混合物を約1時間、約0℃で保持することをさらに含む、請求項64から65のいずれか一項に記載の方法。
- 請求項54から67のいずれか一項に従って作製された2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンを含む組成物。
- 医薬組成物を作製する方法であって、請求項21から30のいずれか一項に記載の多形または請求項31から42もしくは68のいずれか一項に記載の組成物を、液体形態またはエマルジョン形態に変換することを含む、方法。
- 前記液体形態または前記エマルジョン形態が、経口溶液、液体充填カプセル、または注射可能な溶液として提供される、請求項69に記載の方法。
- 請求項69または70により生成された医薬組成物。
- 図31に実質的に示されるようなXRPDプロットを有する、2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオンの準安定融解非晶質形態。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862747080P | 2018-10-17 | 2018-10-17 | |
US62/747,080 | 2018-10-17 | ||
US201862771570P | 2018-11-26 | 2018-11-26 | |
US62/771,570 | 2018-11-26 | ||
PCT/US2019/056836 WO2020081879A2 (en) | 2018-10-17 | 2019-10-17 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022505257A true JP2022505257A (ja) | 2022-01-14 |
JPWO2020081879A5 JPWO2020081879A5 (ja) | 2022-10-12 |
Family
ID=68503208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021521219A Pending JP2022505257A (ja) | 2018-10-17 | 2019-10-17 | α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン |
Country Status (22)
Country | Link |
---|---|
US (4) | US11174212B2 (ja) |
EP (2) | EP3866772B1 (ja) |
JP (1) | JP2022505257A (ja) |
KR (1) | KR20210076956A (ja) |
CN (1) | CN113365616A (ja) |
AU (1) | AU2019362010A1 (ja) |
BR (1) | BR112021007153A2 (ja) |
CA (1) | CA3116866A1 (ja) |
CL (1) | CL2021000948A1 (ja) |
CO (1) | CO2021006356A2 (ja) |
DK (1) | DK3866772T3 (ja) |
EC (1) | ECSP21034596A (ja) |
ES (1) | ES2968957T3 (ja) |
FI (1) | FI3866772T3 (ja) |
IL (1) | IL282375A (ja) |
MX (1) | MX2021004329A (ja) |
PE (1) | PE20211600A1 (ja) |
PH (1) | PH12021550859A1 (ja) |
PL (1) | PL3866772T3 (ja) |
SG (1) | SG11202103887VA (ja) |
TN (1) | TN2021000075A1 (ja) |
WO (1) | WO2020081879A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3456707B1 (en) | 2007-11-06 | 2020-04-15 | PTC Therapeutics, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
CN113365616A (zh) | 2018-10-17 | 2021-09-07 | Ptc医疗公司 | 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮 |
WO2021077034A1 (en) * | 2019-10-18 | 2021-04-22 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders |
KR20240032997A (ko) | 2021-07-08 | 2024-03-12 | 피티씨 테라퓨틱스, 인크. | 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물 |
WO2024050725A1 (en) | 2022-09-07 | 2024-03-14 | Ptc Therapeutics, Inc. | Methods of producing 2, 3, 5, 6-alkyl-1, 4-benzoquinones |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08768B2 (ja) | 1989-08-24 | 1996-01-10 | 武田薬品工業株式会社 | 神経成長因子分泌誘導剤 |
US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
WO1998002149A2 (en) | 1996-07-11 | 1998-01-22 | Takeda Chemical Industries, Ltd. | Use of idebenone and analogues against beta amyloid induced cytotoxicity |
CA2332806A1 (en) | 1998-05-22 | 1999-12-02 | Natalie Dales | Bioreductive cytotoxic agents |
US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
ATE328283T1 (de) | 2002-07-01 | 2006-06-15 | Santhera Pharmaceuticals Ch | Screeningverfahren und verbindungen zur behandlung von friedreich ataxia |
JP4599292B2 (ja) | 2002-10-30 | 2010-12-15 | エジソン ファーマシューティカルズ, インコーポレイテッド | 物理的−化学的特性に基づく治療用化合物の同定 |
CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
ES2714900T3 (es) | 2005-06-01 | 2019-05-30 | Bioelectron Tech Corp | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
WO2007035496A1 (en) * | 2005-09-15 | 2007-03-29 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
US20070203080A1 (en) | 2006-02-15 | 2007-08-30 | The Regents Of The University Of California | New Drug Delivery System for Crossing the Blood Brain Barrier |
JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
CN101610782A (zh) | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
EP3456707B1 (en) | 2007-11-06 | 2020-04-15 | PTC Therapeutics, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
CA2710253A1 (en) | 2008-01-07 | 2009-07-16 | Centocor Ortho Biotech Inc. | Method of treating erythropoietin hyporesponsive anemias |
US8952071B2 (en) | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
JP5710277B2 (ja) | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体 |
US20110046156A1 (en) | 2008-03-05 | 2011-02-24 | Miller Guy M | Treatment of hearing and balance impairments with redox-active therapeutics |
WO2009143268A2 (en) | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US20100010100A1 (en) | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
DK2362875T3 (en) | 2008-10-28 | 2015-11-30 | Edison Pharmaceuticals Inc | METHOD OF PRODUCING ALPHA-tocotrienol AND DERIVATIVES |
US20100273892A1 (en) | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
WO2010126910A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
EP2609921A1 (en) | 2009-06-25 | 2013-07-03 | Ampere Life Sciences, Inc. | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
CN102647981B (zh) | 2009-08-26 | 2016-09-28 | 爱迪生制药有限公司 | 预防和治疗脑缺血的方法 |
US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
US20110263720A1 (en) | 2010-03-09 | 2011-10-27 | Penwest Pharmaceuticals Co. | Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
EA201201374A1 (ru) | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
MY183449A (en) | 2010-04-27 | 2021-02-18 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
WO2012009271A1 (en) | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
JP6045494B2 (ja) | 2010-08-06 | 2016-12-14 | エジソン ファーマシューティカルズ, インコーポレイテッド | ナフトキノンによるミトコンドリア病の処置 |
WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
US20150057363A1 (en) | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
US9162957B2 (en) | 2011-07-19 | 2015-10-20 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
JP6313791B2 (ja) | 2013-03-08 | 2018-04-18 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 皮膚科学的使用のためのレゾルシノール化合物 |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
EP3004071A1 (en) | 2013-05-31 | 2016-04-13 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
RU2770091C2 (ru) | 2014-12-16 | 2022-04-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида |
JP2018502127A (ja) | 2015-01-12 | 2018-01-25 | バイオエレクトロン テクノロジー コーポレイション | 放射線被曝に対する防護のためのキノン |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
WO2017123823A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors |
WO2017123822A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
WO2018081644A1 (en) | 2016-10-28 | 2018-05-03 | Bioelectron Technology Corporation | Methods of analyzing p-hydroquinone levels and ratios |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
CA3097114A1 (en) * | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
US20180333389A1 (en) | 2017-04-14 | 2018-11-22 | Bioelectron Technology Corporation | Vitamin e compositions and methods of use therefor |
CN113365616A (zh) | 2018-10-17 | 2021-09-07 | Ptc医疗公司 | 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮 |
EP3983385B1 (en) | 2019-06-13 | 2023-08-30 | PTC Therapeutics, Inc. | Naphthoquinone derivatives for treatment of oxidative stress disorders |
WO2021077034A1 (en) | 2019-10-18 | 2021-04-22 | Ptc Therapeutics, Inc. | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders |
-
2019
- 2019-10-17 CN CN201980083477.1A patent/CN113365616A/zh active Pending
- 2019-10-17 KR KR1020217014520A patent/KR20210076956A/ko active Search and Examination
- 2019-10-17 MX MX2021004329A patent/MX2021004329A/es unknown
- 2019-10-17 JP JP2021521219A patent/JP2022505257A/ja active Pending
- 2019-10-17 TN TNP/2021/000075A patent/TN2021000075A1/en unknown
- 2019-10-17 BR BR112021007153-9A patent/BR112021007153A2/pt unknown
- 2019-10-17 SG SG11202103887VA patent/SG11202103887VA/en unknown
- 2019-10-17 AU AU2019362010A patent/AU2019362010A1/en active Pending
- 2019-10-17 EP EP19801443.3A patent/EP3866772B1/en active Active
- 2019-10-17 PE PE2021000524A patent/PE20211600A1/es unknown
- 2019-10-17 ES ES19801443T patent/ES2968957T3/es active Active
- 2019-10-17 CA CA3116866A patent/CA3116866A1/en active Pending
- 2019-10-17 WO PCT/US2019/056836 patent/WO2020081879A2/en unknown
- 2019-10-17 EP EP23193936.4A patent/EP4257190A3/en active Pending
- 2019-10-17 DK DK19801443.3T patent/DK3866772T3/da active
- 2019-10-17 PL PL19801443.3T patent/PL3866772T3/pl unknown
- 2019-10-17 FI FIEP19801443.3T patent/FI3866772T3/fi active
-
2021
- 2021-03-30 US US17/218,042 patent/US11174212B2/en active Active
- 2021-04-16 CL CL2021000948A patent/CL2021000948A1/es unknown
- 2021-04-16 PH PH12021550859A patent/PH12021550859A1/en unknown
- 2021-04-18 IL IL282375A patent/IL282375A/en unknown
- 2021-05-14 CO CONC2021/0006356A patent/CO2021006356A2/es unknown
- 2021-05-14 EC ECSENADI202134596A patent/ECSP21034596A/es unknown
- 2021-11-10 US US17/523,880 patent/US11667596B2/en active Active
-
2022
- 2022-01-25 US US17/584,362 patent/US11746077B2/en active Active
-
2023
- 2023-07-05 US US18/347,068 patent/US20230339835A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL282375A (en) | 2021-06-30 |
FI3866772T3 (fi) | 2024-01-11 |
BR112021007153A2 (pt) | 2021-07-20 |
MX2021004329A (es) | 2021-06-08 |
PL3866772T3 (pl) | 2024-04-08 |
EP4257190A3 (en) | 2024-01-03 |
EP4257190A2 (en) | 2023-10-11 |
KR20210076956A (ko) | 2021-06-24 |
US20210276937A1 (en) | 2021-09-09 |
US20220106248A1 (en) | 2022-04-07 |
WO2020081879A3 (en) | 2020-07-23 |
CA3116866A1 (en) | 2020-04-23 |
TN2021000075A1 (en) | 2023-01-05 |
EP3866772A2 (en) | 2021-08-25 |
EP3866772B1 (en) | 2023-10-11 |
PE20211600A1 (es) | 2021-08-18 |
CO2021006356A2 (es) | 2021-08-09 |
ECSP21034596A (es) | 2021-06-30 |
SG11202103887VA (en) | 2021-05-28 |
WO2020081879A2 (en) | 2020-04-23 |
AU2019362010A1 (en) | 2021-05-20 |
ES2968957T3 (es) | 2024-05-14 |
US20230339835A1 (en) | 2023-10-26 |
CL2021000948A1 (es) | 2021-11-26 |
US11667596B2 (en) | 2023-06-06 |
US11174212B2 (en) | 2021-11-16 |
DK3866772T3 (da) | 2024-01-15 |
US20220220054A1 (en) | 2022-07-14 |
CN113365616A (zh) | 2021-09-07 |
US11746077B2 (en) | 2023-09-05 |
PH12021550859A1 (en) | 2021-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022505257A (ja) | α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン | |
JP6665169B2 (ja) | 新規化合物αvβ6インテグリンアンタゴニスト | |
EA026541B1 (ru) | Дигидрат соединения бензотиофена, его применение и содержащая его фармацевтическая композиция | |
JP2019509305A (ja) | インテグリンアンタゴニストとしてのナフチリジン | |
CN105153122A (zh) | [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用 | |
KR20070007888A (ko) | 결정질 n-데스메틸클로자핀 | |
AU2015207867A1 (en) | Compounds and methods for the treatment of pain and other diseases | |
JP2018203648A (ja) | ヘテロシクリデンアセトアミド誘導体の結晶 | |
JP2014051517A (ja) | デフェラシロックス(icl670a)の多形形態 | |
JP2013520488A (ja) | ペルフェナジン−gabaのトリメシラート塩の結晶性形態物及びその製法方法 | |
EP2830608B1 (en) | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation | |
JP2018527363A (ja) | リナグリプチン結晶形及びこの製造方法 | |
JP2005532280A (ja) | 化合物 | |
HUE034721T2 (hu) | Szubsztituált 2-alkil-1-oxo-N-fenil-3-heteroaril-1,2,3,4-tetrahidroizokinolin-4-karboxamidok maláriaellenes terápiákhoz | |
TW201726651A (zh) | 2,3,4,5-四氫吡啶-6-胺衍生物 | |
EP3141235A1 (en) | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide | |
AU2004265104B2 (en) | Stable polymorph of bifeprunox mesilate | |
EP3447045B1 (en) | 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria | |
EA027972B1 (ru) | Новая кристаллическая форма | |
WO2001094311A1 (fr) | Cytoprotecteurs | |
WO2004016583A1 (en) | Substituted glycine derivatives for use as medicaments | |
JPH02502728A (ja) | アルドースレダクターゼ抑制剤としてのn―ナフトイルグリシン | |
WO2024099403A1 (zh) | 一种具有软药性质的硫醚类化合物、药物组合物及其用途 | |
CA3103910A1 (en) | Oga inhibitor compounds | |
JPH11240882A (ja) | 縮合ピリダジン誘導体、その製造法および用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221003 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230925 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240516 |